Investigating Idetrexed and Olaparib in Patients With Ovarian Cancer

Phase 1RecruitingNCT06976892

Institute of Cancer Research, United Kingdom33 enrolled

Overview

Two drugs called Idetrexed and olaparib are being evaluated. Idetrexed is a type of drug called an "aFR-targeted thymidylate synthase inhibitor". Idetrexed has been designed to selectively target cancer cells that have a protein called folate receptor on the surface of cancer cells. Thymidylate synthase is key to cancer cells for creating new DNA when they multiply. Blocking the action of thymidylate synthase with a drug like Idetrexed may therefore stop cancers from growing by damaging DNA in cancer cells. Olaparib is a type of drug called a "PARP inhibitor". It prevents cells repairing DNA damage. This leads to cells dying. Combining Idetrexed and olaparib should increase the number of cancer cells dying, especially those cells that have a lot of folate receptors. Cancer cells with a high number of folate receptors should be targeted more than normal healthy cells.

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

High Grade Serous Ovarian Cancer

Interventions

Eligibility

Sex: FEMALEMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Histologically or cytologically proven high grade serous ovarian cancer refractory to conventional treatment, or for which no conventional therapy exists or is declined by the patient. * Measurable (as defined by RECIST v1.1) or evaluable (based on tumour markers) disease. * Life expectancy of at least 12 weeks. * World Health Organisation (WHO) performance status of 0-1 (Appendix 1 of Protocol). * Haematological and biochemical indices within the ranges shown in Protocol section 4.1.1). These measurements must be performed within one week (Day -7 to Day 1) prior to the patient's first dose of IMP. Normal (no clinically significant abnormalities) 12-lead ECG, QTcF interval \<470 ms * Pulmonary function test FVC of \>70%, DLCOc (DLCO corrected for Hb) of \>60%. * 18 years or over. * Written (signed and dated) informed consent and be capable of co-operating with treatment and follow-up. * For dose expansion patients only, they must have medium to high α-folate receptor expression according to the Ventana FOLR1-2.1 IHC assay. Exclusion Criteria: * Radiotherapy (except for palliative reasons), endocrine therapy, immunotherapy or chemotherapy during the previous four weeks (six weeks for nitrosoureas, Mitomycin-C) and 4 weeks for investigational medicinal products) before treatment. * Ongoing toxic manifestations of previous treatments. Exceptions to this are alopecia or certain Grade 1 toxicities, which in the opinion of the Investigator and the DDU should not exclude the patient. * Patients with new brain metastases. Patients with treated (surgically excised or irradiated) and stable brain metastases are eligible as long as the treatment was at least 4 weeks prior to initiation of study drug and brain MRI within 2 weeks of initiation of study drug is negative for new metastases. * Patients with pulmonary metastases. * History of thoracic radiation or other history likely to create pre-existing lung disease * Presence of significant clinical ascites and/or pleural effusions. * Female patients of child-bearing potential (or are already pregnant or lactating). However, those patients who have a negative serum or urine pregnancy test before enrolment and agree to use two forms of contraception (one effective form plus a barrier method) \[oral, injected or implanted hormonal contraception and condom; intra-uterine device and condom; diaphragm with spermicidal gel and condom\] or agree to sexual abstinence (see Protocol Section 16.5 - Appendix 5), effective from signing the consent form, throughout the trial and for six months afterwards are considered eligible. * Major thoracic or abdominal surgery from which the patient has not yet recovered. * Patients with sub-acute bowel obstruction. * Organ transplant patients. * At high medical risk because of non-malignant systemic disease including active uncontrolled infection. * Known to be serologically positive for hepatitis B, hepatitis C or human immunodeficiency virus (HIV). * Patients with history of QT prolongation, clinically significant VT, VF, heart block, MI within 1 year, CHF NYHA Class III or IV, unstable angina, angina within 6 months, or other evidence of clinically significant coronary artery disease/ * Is a participant or plans to participate in another interventional clinical trial, whilst taking part in this Phase I/Ib study of Idetrexed and Olaparib. Participation in an observational trial would be acceptable. * Inability to tolerate Olaparib. * Any other condition which in the Investigator's opinion would not make the patient a good candidate for the clinical trial. * Confirmed, current COVID-19 infection.

Outcomes

Primary Outcomes

Propose a recommended dose/schedule for Phase II evaluation of the combination of Idetrexed and Olaparib

Endpoint: Maximum tolerated dose/ schedule (MTD) of the combination of Idetrexed and Olaparib based on dose-limiting toxicities (DLT) with target acceptable DLT rate of 25%, and the Recommended Phase II dose (RP2D) and schedule (Dose Escalation only).

Time frame: End of Cycle 2 (each cycle is 28 days)

Assess the safety and toxicity profile of Idetrexed and Olaparib

Endpoint: determining causality of each adverse event to Idetrexed and Olaparib and grading severity according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 (Dose Escalation and Dose Expansion).

Time frame: End of Cycle 6 (each cycle is 28 days)

Evaluate the preliminary anti-tumour activity of the combination of Idetrexed and Olaparib in alpha folate receptor overexpressing high grade serous ovarian cancer

Endpoint: Objective response rate by the occurrence of Best Overall Response (BOR) per RECIST 1.1 criteria (Dose Expansion only).

Time frame: Until patient withdraws due to radiological progression, or begins new line of therapy.

Secondary Outcomes

Evaluate antitumour activity of the combination of Idetrexed and Olaparib

Endpoint: Progression Free Survival (PFS).

Time frame: From date of enrolment until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 60 months

Evaluate the preliminary anti-tumour activity of the combination of Idetrexed and Olaparib in ovarian cancer irrespective of alpha folate receptor expression status

Objective response rate.

Time frame: From date of enrolment until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 60 months.

CA125 responses

Measurement of CA125 levels.